CYTOKINETICS INC — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Cytokinetics has adopted an Insider Trading Policy effective September 20, 2026, establishing governance rules for securities trading by directors, officers, employees, and their family members and controlled entities. The policy prohibits trading on material nonpublic information (MNPI), imposes quarterly and special blackout periods, requires pre-clearance for certain executives, mandates Rule 10b5-1 trading plans for Board Members and Corporate Steering Committee members, and restricts short sales, options trading, pledging, and tipping. Violations carry civil penalties up to 3× profits gained or loss avoided (or $1M minimum for the company) plus criminal penalties up to $5M for individuals or $25M for the company.
Why this rating
Policy adoption is routine administrative/governance disclosure with no business or financial impact. Standard compliance document; no transaction, acquisition, or operational change disclosed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.